Literature DB >> 26351136

Screening of HELQ in breast and ovarian cancer families.

Liisa M Pelttari1, Laura Kinnunen1, Johanna I Kiiski1, Sofia Khan1, Carl Blomqvist2, Kristiina Aittomäki3, Heli Nevanlinna4.   

Abstract

Several high and moderate risk alleles have been identified for breast and ovarian cancer predisposition and most of them encode proteins that function in DNA repair. A prospective candidate for breast and ovarian cancer susceptibility is the HELQ helicase that has a role in the resolution of DNA interstrand cross-links. HELQ interacts with the RAD51 paralog complex BCDX2. Two components of the complex, RAD51C and RAD51D, increase the risk of ovarian cancer especially, and the other two, RAD51B and XRCC2 have been associated with breast cancer risk. To investigate the role of HELQ in cancer predisposition, we screened the gene for germline variation in 185 Finnish breast or ovarian cancer families and performed haplotype analyses for 1517 breast cancer cases, 308 ovarian cancer cases, and 1234 population controls using five common polymorphisms at the HELQ gene locus. No truncating mutations were identified among the families. One putatively pathogenic missense mutation c.1309A>G was identified but no additional carriers were observed in the subsequent genotyping of 332 familial breast or ovarian cancer patients. Furthermore, the haplotype distribution did not differ between breast or ovarian cancer cases and population controls. Our results indicate that HELQ is not a major breast and ovarian cancer susceptibility gene in the Finnish population. However, we cannot rule out rare risk-variants in the Finnish or other populations and larger datasets are needed to further assess the role of HELQ especially in ovarian cancer predisposition.

Entities:  

Keywords:  Breast cancer; DNA repair; HELQ; Ovarian cancer

Mesh:

Substances:

Year:  2016        PMID: 26351136     DOI: 10.1007/s10689-015-9838-4

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  21 in total

1.  A CHEK2 genetic variant contributing to a substantial fraction of familial breast cancer.

Authors:  Pia Vahteristo; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Salla Ojala; Outi Kilpivaara; Anitta Tamminen; Juha Kononen; Kristiina Aittomäki; Päivi Heikkilä; Kaija Holli; Carl Blomqvist; Jiri Bartek; Olli-P Kallioniemi; Heli Nevanlinna
Journal:  Am J Hum Genet       Date:  2002-07-28       Impact factor: 11.025

Review 2.  Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway.

Authors:  Hyungjin Kim; Alan D D'Andrea
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

3.  MutationTaster evaluates disease-causing potential of sequence alterations.

Authors:  Jana Marie Schwarz; Christian Rödelsperger; Markus Schuelke; Dominik Seelow
Journal:  Nat Methods       Date:  2010-08       Impact factor: 28.547

4.  Genetic variants in DNA repair pathways and risk of upper aerodigestive tract cancers: combined analysis of data from two genome-wide association studies in European populations.

Authors:  Marie-Claude Babron; Rémi Kazma; Valérie Gaborieau; James McKay; Paul Brennan; Alain Sarasin; Simone Benhamou
Journal:  Carcinogenesis       Date:  2014-03-21       Impact factor: 4.944

5.  RAD51C is a susceptibility gene for ovarian cancer.

Authors:  Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna
Journal:  Hum Mol Genet       Date:  2011-05-25       Impact factor: 6.150

6.  A Finnish founder mutation in RAD51D: analysis in breast, ovarian, prostate, and colorectal cancer.

Authors:  Liisa M Pelttari; Johanna Kiiski; Riikka Nurminen; Anne Kallioniemi; Johanna Schleutker; Alexandra Gylfe; Lauri A Aaltonen; Arto Leminen; Päivi Heikkilä; Carl Blomqvist; Ralf Bützow; Kristiina Aittomäki; Heli Nevanlinna
Journal:  J Med Genet       Date:  2012-05-31       Impact factor: 6.318

7.  Correlation of CHEK2 protein expression and c.1100delC mutation status with tumor characteristics among unselected breast cancer patients.

Authors:  Outi Kilpivaara; Jirina Bartkova; Hannaleena Eerola; Kirsi Syrjäkoski; Pia Vahteristo; Jiri Lukas; Carl Blomqvist; Kaija Holli; Päivi Heikkilä; Guido Sauter; Olli-Pekka Kallioniemi; Jiri Bartek; Heli Nevanlinna
Journal:  Int J Cancer       Date:  2005-02-10       Impact factor: 7.396

8.  Low proportion of BRCA1 and BRCA2 mutations in Finnish breast cancer families: evidence for additional susceptibility genes.

Authors:  P Vehmanen; L S Friedman; H Eerola; M McClure; B Ward; L Sarantaus; T Kainu; K Syrjäkoski; S Pyrhönen; O P Kallioniemi; T Muhonen; M Luce; T S Frank; H Nevanlinna
Journal:  Hum Mol Genet       Date:  1997-12       Impact factor: 6.150

9.  Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs.

Authors:  Kei-ichi Takata; Shelley Reh; Junya Tomida; Maria D Person; Richard D Wood
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

10.  HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis.

Authors:  Carrie A Adelman; Rafal L Lolo; Nicolai J Birkbak; Olga Murina; Kenichiro Matsuzaki; Zuzana Horejsi; Kalindi Parmar; Valérie Borel; J Mark Skehel; Gordon Stamp; Alan D'Andrea; Alessandro A Sartori; Charles Swanton; Simon J Boulton
Journal:  Nature       Date:  2013-09-04       Impact factor: 49.962

View more
  2 in total

1.  Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.

Authors:  Yosr Hamdi; Penny Soucy; Véronique Adoue; Kyriaki Michailidou; Sander Canisius; Audrey Lemaçon; Arnaud Droit; Irene L Andrulis; Hoda Anton-Culver; Volker Arndt; Caroline Baynes; Carl Blomqvist; Natalia V Bogdanova; Stig E Bojesen; Manjeet K Bolla; Bernardo Bonanni; Anne-Lise Borresen-Dale; Judith S Brand; Hiltrud Brauch; Hermann Brenner; Annegien Broeks; Barbara Burwinkel; Jenny Chang-Claude; Fergus J Couch; Angela Cox; Simon S Cross; Kamila Czene; Hatef Darabi; Joe Dennis; Peter Devilee; Thilo Dörk; Isabel Dos-Santos-Silva; Mikael Eriksson; Peter A Fasching; Jonine Figueroa; Henrik Flyger; Montserrat García-Closas; Graham G Giles; Mark S Goldberg; Anna González-Neira; Grethe Grenaker-Alnæs; Pascal Guénel; Lothar Haeberle; Christopher A Haiman; Ute Hamann; Emily Hallberg; Maartje J Hooning; John L Hopper; Anna Jakubowska; Michael Jones; Maria Kabisch; Vesa Kataja; Diether Lambrechts; Loic Le Marchand; Annika Lindblom; Jan Lubinski; Arto Mannermaa; Mel Maranian; Sara Margolin; Frederik Marme; Roger L Milne; Susan L Neuhausen; Heli Nevanlinna; Patrick Neven; Curtis Olswold; Julian Peto; Dijana Plaseska-Karanfilska; Katri Pylkäs; Paolo Radice; Anja Rudolph; Elinor J Sawyer; Marjanka K Schmidt; Xiao-Ou Shu; Melissa C Southey; Anthony Swerdlow; Rob A E M Tollenaar; Ian Tomlinson; Diana Torres; Thérèse Truong; Celine Vachon; Ans M W Van Den Ouweland; Qin Wang; Robert Winqvist; Wei Zheng; Javier Benitez; Georgia Chenevix-Trench; Alison M Dunning; Paul D P Pharoah; Vessela Kristensen; Per Hall; Douglas F Easton; Tomi Pastinen; Silje Nord; Jacques Simard
Journal:  Oncotarget       Date:  2016-12-06

2.  Uncovering and characterizing splice variants associated with survival in lung cancer patients.

Authors:  Sean West; Sushil Kumar; Surinder K Batra; Hesham Ali; Dario Ghersi
Journal:  PLoS Comput Biol       Date:  2019-10-25       Impact factor: 4.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.